Acadia Pharmaceuticals Stock Surges After Positive Regulatory News

Acadia Pharmaceuticals (ACAD) stock rose by over 12% on Friday after the European Medicines Agency's CHMP recommended approval for its drug Daybue to treat neurobehavioral symptoms of Rett syndrome in Europe. This could expand Acadia’s market and potentially boost revenue from a treatment already generating $101 million in Q1 sales.

By James Brumley · Motley Fool · June 26, 2026, 16:17 UTC

Acadia Pharmaceuticals Stock Surges After Positive Regulatory News

Tickers: $ACAD

Topics: Daybue European Medicines Agency (EMA) neurobehavioral symptoms Rett syndrome

Read the full article at Motley Fool

More World news

EnterpriseDB Hires CMRD Engineering Team to Strengthen Sovereign AI Governance PR Newswire · November 12, 2026, 18:36 UTC
Alliant Credit Union Executive Meredith Ritchie Named 2027 Chicago Titan 100 Honoree PR Newswire · November 12, 2026, 18:36 UTC
Fed's Schmid Argues Construction Productivity is Key to Housing Affordability Over Interest Rate Cuts Seeking Alpha · November 12, 2026, 18:33 UTC
PROG Holdings Reports 59% GMV Growth and Announces $100 Million Share Repurchase Program Motley Fool · November 12, 2026, 18:30 UTC
Corteva Shares Plunge Over Q3 Earnings Miss and Pricing Pressures Motley Fool · November 12, 2026, 18:31 UTC
Teekay Tankers Shares Decline Despite Q3 Earnings Beat and New Vessel Orders Seeking Alpha · November 12, 2026, 18:27 UTC
U.S. 30-Year Treasury Auction Yields Rise as Demand Weakens Seeking Alpha · November 12, 2026, 18:30 UTC
Nvidia Names Colette Kress Interim CEO Following Jensen Huang's Resignation Motley Fool · November 12, 2026, 18:26 UTC
Bit Digital Reports Q3 2026 Net Income of $28.5 Million Amid Revenue Decline Motley Fool · November 12, 2026, 18:26 UTC
EZCORP Reports Strong Q4 2026 Results with Significant EBITDA and Revenue Growth Motley Fool · November 12, 2026, 18:16 UTC